Compare Cipla with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ABBOTT INDIA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ABBOTT INDIA CIPLA/
ABBOTT INDIA
 
P/E (TTM) x 23.9 51.2 46.6% View Chart
P/BV x 2.4 12.4 19.7% View Chart
Dividend Yield % 0.7 0.6 118.6%  

Financials

 CIPLA   ABBOTT INDIA
EQUITY SHARE DATA
    CIPLA
Mar-19
ABBOTT INDIA
Mar-19
CIPLA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6788,834 7.7%   
Low Rs4845,458 8.9%   
Sales per share (Unadj.) Rs198.21,731.1 11.5%  
Earnings per share (Unadj.) Rs18.5211.9 8.7%  
Cash flow per share (Unadj.) Rs35.0219.9 15.9%  
Dividends per share (Unadj.) Rs3.0065.00 4.6%  
Dividend yield (eoy) %0.50.9 56.8%  
Book value per share (Unadj.) Rs186.3945.2 19.7%  
Shares outstanding (eoy) m805.7021.25 3,791.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.1 71.0%   
Avg P/E ratio x31.433.7 93.0%  
P/CF ratio (eoy) x16.632.5 51.1%  
Price / Book Value ratio x3.17.6 41.2%  
Dividend payout %16.230.7 52.8%   
Avg Mkt Cap Rs m468,031151,848 308.2%   
No. of employees `00022.63.5 649.8%   
Total wages/salary Rs m28,5654,356 655.8%   
Avg. sales/employee Rs Th7,053.110,555.5 66.8%   
Avg. wages/employee Rs Th1,261.51,249.9 100.9%   
Avg. net profit/employee Rs Th659.11,292.2 51.0%   
INCOME DATA
Net Sales Rs m159,71036,786 434.2%  
Other income Rs m4,7661,133 420.7%   
Total revenues Rs m164,47537,919 433.8%   
Gross profit Rs m30,9736,047 512.2%  
Depreciation Rs m13,263169 7,838.7%   
Interest Rs m1,68423 7,485.8%   
Profit before tax Rs m20,7916,989 297.5%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6952,485 229.2%   
Profit after tax Rs m14,9244,503 331.4%  
Gross profit margin %19.416.4 118.0%  
Effective tax rate %27.435.6 77.0%   
Net profit margin %9.312.2 76.3%  
BALANCE SHEET DATA
Current assets Rs m124,26627,610 450.1%   
Current liabilities Rs m37,7158,569 440.1%   
Net working cap to sales %54.251.8 104.7%  
Current ratio x3.33.2 102.3%  
Inventory Days Days9160 150.5%  
Debtors Days Days9527 346.3%  
Net fixed assets Rs m105,1901,057 9,952.8%   
Share capital Rs m1,611213 758.3%   
"Free" reserves Rs m148,51119,873 747.3%   
Net worth Rs m150,12320,086 747.4%   
Long term debt Rs m38,3010-   
Total assets Rs m239,63329,409 814.8%  
Interest coverage x13.3311.6 4.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.3 53.3%   
Return on assets %6.915.4 45.0%  
Return on equity %9.922.4 44.3%  
Return on capital %11.834.9 33.9%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,410369 15,559.8%   
Fx outflow Rs m19,0414,918 387.1%   
Net fx Rs m38,368-4,549 -843.4%   
CASH FLOW
From Operations Rs m16,9114,991 338.8%  
From Investments Rs m-16,687-2,570 649.3%  
From Financial Activity Rs m-3,487-1,428 244.2%  
Net Cashflow Rs m-3,451993 -347.4%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 7.9 154.4%  
FIIs % 23.7 0.1 23,700.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.1 153.2%  
Shareholders   161,166 18,270 882.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 11, 2019 (Close)

TRACK CIPLA

CIPLA - SHASUN PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS